Pharmigene (ROCO:7595) Shares Outstanding (EOP): 50.5 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7595 Pharmigene Inc ROCO:7595
54 GF Score
Price NT$6.30
GF Value NT$24.76
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Pharmigene Shares Outstanding (EOP)?

Pharmigene ROCO:7595 -2.33% 54 Shares Outstanding (EOP) is 50.5 Mil as of Dec. 2025. GuruFocus rates ROCO:7595 with a GF Score™ of 54/100 and a GF Value™ of NT$24.76 (Possible Value Trap). The stock has 7 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Pharmigene's shares outstanding for the quarter that ended in Dec. 2025 was 50.5 Mil.

Pharmigene's quarterly shares outstanding stayed the same from Jun. 2025 (50.5 Mil) to Dec. 2025 (50.5 Mil).

Pharmigene's annual shares outstanding stayed the same from Dec. 2024 (50.5 Mil) to Dec. 2025 (50.5 Mil).


Pharmigene  (ROCO:7595) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Pharmigene Shares Outstanding (EOP) Related Terms


Pharmigene Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Pharmigene's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmigene Shares Outstanding (EOP) Chart

Pharmigene Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only 43.47 43.47 50.47 50.47 50.47

Pharmigene Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.47 50.47 50.47 50.47 50.47

ROCO:7595 vs TMO, DHR, IDXX: Shares Outstanding (EOP) Comparison

For the Diagnostics & Research subindustry, Pharmigene's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmigene Shares Outstanding (EOP) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Pharmigene's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Pharmigene's Shares Outstanding (EOP) falls into.


ROCO:7595
54GF Score
Pharmigene Inc ROCO:7595
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmigene Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 50.5 Mil mean?
Pharmigene (ROCO:7595) has a Shares Outstanding (EOP) of 50.5 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Pharmigene and its competitors.
Is Pharmigene's Shares Outstanding (EOP) too high?
Pharmigene's current Shares Outstanding (EOP) is 50.5 Mil. Overall, Pharmigene has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pharmigene's Shares Outstanding (EOP) compare to TMO and DHR?
Pharmigene's Shares Outstanding (EOP) of 50.5 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Medical Diagnostics & Research company?
A good Shares Outstanding (EOP) depends on the Medical Diagnostics & Research industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Pharmigene and its competitors. Pharmigene's current Shares Outstanding (EOP) is 50.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmigene stock overvalued right now?
Based on GuruFocus' analysis, Pharmigene (ROCO:7595) is currently considered Possible Value Trap. The stock's GF Value™ is NT$24.76, compared to a current price of NT$6.30 — trading 74.6% below its estimated fair value. The current Shares Outstanding (EOP) is 50.5 Mil. Pharmigene's overall GF Score™ is 54/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Pharmigene (ROCO:7595), the current Shares Outstanding (EOP) is 50.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmigene (ROCO:7595) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmigene stock appears to be undervalued. The current stock price of NT$6.30 is trading 74.6% below its estimated GF Value™ of NT$24.76. GuruFocus considers Pharmigene to be Possible Value Trap.

Key valuation signals for ROCO:7595:

  • Shares Outstanding (EOP): 50.5 Mil
  • GF Value™: NT$24.76 vs. price of NT$6.30 (74.6% below fair value)
  • GF Score™: 54/100 with 7 warning signs

No single metric tells the full story. See the ROCO:7595 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharmigene Business Description

Address No. 17, Lane 171, Section 2, Jiuzong Road, 4th Floor, Neihu District, Taipei, TWN, 11494
Pharmigene Inc is engaged in the development and sales of pharmaceutical genetic diagnostic products. Also, the company provides medical and drug testing services and equipment.
54GF Score

Get the complete analysis for ROCO:7595

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$6.30
Price
NT$24.76
GF Value